Heightened investor risk aversion due to global geopolitical tensions: The Middle East conflict driving oil prices higher and threatening global growth, coupled with IMF downgrades, makes investors more cautious, potentially impacting valuations and investment flows into clinical-stage biotech companies like CGEM that are not yet profitable.

Potential impact of inflation and supply chain costs: Rising oil prices from the Middle East conflict could indirectly increase operational costs for biotech R&D and future manufacturing, affecting CGEM's financial outlook and burn rate, although this impact might be delayed for a clinical-stage company.

Overall US economic health and market sentiment: Strong US job growth and dipping unemployment can provide a general positive backdrop for the US stock market, potentially mitigating some of the global risk aversion for US-listed companies like CGEM, though direct impact on a pre-revenue biotech is less significant than clinical milestones.